Patent & Trade Mark
Attorneys
Patrick McManamny
Patrick McManamny
Partner


Level 14, 90 Collins St
Melbourne VIC 3000 AUSTRALIA
Tel +61 3 8618 4132
Fax +61 3 8618 4199
Recent Publications
16 Jan 2017
Inventorship has been described as “one of muddiest concepts in the muddy metaphysics of the patent law.” Mueller Brass Co. v. Reading Industries, Inc., 352 F.Supp. 1357, 1372 (E.D.Pa. 1972). Determining inventorship is a complex issue that is undertaken on a much stricter basis than authorship of a scientific publication. It can also be a particularly contentious issue when people are not named as inventors. Not only can this lead to alienation, but it can also lead to legal issues. For example, a patent may be invalid if incorrect inventors are intentionally named. During litigation, a defendant may also be able to identify an unnamed inventor and obtain an assignment from them, thereby qualifying as a co-owner of the patent and no longer subject to the litigation.

12 Sep 2016
In August 2015, we reported on a decision of the Australian Patent Office dealing with three applications by Abbvie Biotechnology for extensions of term to its Australia Patents 2012261708, 2013203420 and 2013257402 on the basis of ‘Swiss-Style’ claims.

06 Sep 2016
Monoclonal antibodies are important human therapeutic agents and represent some of the largest selling drugs in the world. Patents relating to antibodies are treated differently to some other compounds in some jurisdictions. This article touches on some of the important requirements for antibody patenting in some major Asian jurisdictions, namely Japan, China and South Korea.

Dr Patrick McManamny regularly counsels clients in relation to filing and management of international patent portfolios, freedom-to-operate issues, patentability and due diligence.  He has substantial experience in protecting and conducting due diligence in relation to biological therapeutics such as antibodies, proteins, peptides and stem cells and processes for their manufacture.  Patrick also has experience in diagnostics and drug screening methods.

His clients include large multi-national clients, start-up companies and research institutes.  Patrick has also served a brief period as in-house counsel, which provided valuable insight into the responsibilities of this role.

He has experience in developing and managing complex patent portfolios, including developing strategies to coincide with regulatory filings.  He also regularly leads teams in conducting large due diligence and freedom-to-operate analysis projects.
 
His approach to resolving legal issues revolves around reaching the solution which best meets his client's business needs.  Patrick’s technical expertise arise from his PhD primarily focused molecular biology and physiology.

Patrick is a registered patent attorney in Australia and New Zealand.

Education
  • BSc from La Trobe University majoring in genetics and zoology.
  • Honours and PhD at Monash Institute of Reproduction and Development (now Monash Institute of Medical Research). 
  • Graduate Diploma in Intellectual Property Law from the University of Melbourne
Key Areas of Expertise
  • Biological therapies including antibodies, proteins, peptides, stem cells
  • Manufacturing processes for biologicals 
  • Diagnostics
  • Drug-screening methods

Industry Focus

Professional Affiliations

  • Member Institute of Patent and Trade Mark Attorneys of Australia
  • Member Intellectual Property Society of Australia and New Zealand
  • Member of AusBiotech